How Skyrizi Works and Why Side Effects Occur
Skyrizi (risankizumab-rzaa) is an IL-23 inhibitor used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis by blocking inflammation signals. Common side effects stem from its immune suppression, increasing infection risk and mild injection-site reactions.[1]
Most Frequent Side Effects in Clinical Trials
Upper respiratory infections affect about 15-20% of patients, including colds and sinus issues. Headache occurs in 10-15%, and fatigue in around 5-10%. These are typically mild and resolve without stopping treatment.[1][2]
Injection-Site Reactions
Redness, itching, pain, bruising, or swelling at the injection site happen in 5-10% of users, usually within days of the subcutaneous shot. They fade quickly and rarely lead to discontinuation.[1]
Gastrointestinal Issues for IBD Patients
For Crohn's or ulcerative colitis, nausea (up to 10%), diarrhea, or abdominal pain occur more often than in psoriasis patients, linked to gut inflammation reduction.[2]
Fungal and Other Infections
Oral thrush or other fungal infections appear in 1-3%, while serious infections like tuberculosis are rare (less than 1%) but monitored closely.[1][2]
Differences Across Conditions
Psoriasis trials report higher respiratory infections; IBD studies show more GI effects. Pediatric data is limited, but adult patterns hold.[2]
What Happens If Side Effects Persist
Most resolve in weeks. Consult a doctor for worsening infections, severe diarrhea, or allergic signs like rash/swelling. No black-box warnings, but avoid live vaccines.[1]
Sources
[1] Skyrizi Prescribing Information (FDA)
[2] Skyrizi Clinical Trial Data (AbbVie)